Prime Equity Research Initiates Coverage on AtheroNova Inc.
NEW YORK, Dec. 8, 2011 /PRNewswire/ -- Kipley J. Lytel, CFA and Senior Analyst with New York based independent research firm Prime Equity Research, LLC, has initiated research coverage on AtheroNova Inc. (OTCBB: AHRO).
For free access to the report and information on Prime Equity Research, LLC, please visit the Company's website. Interested parties may obtain the report at www.primeequityresearch.com.
Prime Equity Research advises investors to exercise a reasonable degree of due diligence before trading in the equities of any public company, including carefully reading entire analyst reports and report disclosures, and then only in conjunction with advice from a registered financial advisor or broker. Prime Equity Research further advises that any analyst rating, recommendation, target valuation, price target or opinion should be considered merely a portion of an investor's total investigative process.
About AtheroNova Inc.
AtheroNova Inc. is a development stage company focused on the discovery, research, development and licensing of novel compounds designed to reduce or eliminate atherosclerotic plaque deposits. AtheroNova has developed intellectual property for a class of compounds that has the potential to significantly reduce the incidence and severity of atherosclerosis. The company was founded in 2006 and is based in Irvine, California.
Additional information can be found on the company's website at www.atheronova.com.
About Prime Equity Research
Prime Equity Research was founded and is managed by a team that has been actively involved in the research and finance industry for over 20 years -- dating back to the origins of corporate-sponsored research. Our business is rooted in principles of integrity and fundamentals-driven markets. Our seasoned pool of equity securities analysts have extensive securities market research experience, and are highly qualified and credentialed CFA (Chartered Financial Analyst) charter holders or MBAs. The research we provide is as comprehensive, and unbiased as any on the market. Our reports and ratings are used by both institutional and individual investors to obtain accurate, independently-compiled securities data and takes steps to ensure the independence and integrity of published research that exceed those of the CFA Institute Code of Ethics and Standards of Professional Conduct and the CFA-NIRI Guidelines, by following the exacting "Standards for Independent Research Providers", which are also in accordance with guidance set forth by U.S. Securities and Exchange Commission's Advisory Committee on Smaller Public Companies.
Statements in this press release may be "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "optimizing," "potential," "anticipate," "goal," "intend" and similar expressions, as they relate to the company or its management, identify forward-looking statements. These statements are based on current expectations, estimates and projections about the company's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Actual outcomes and results may, and probably will, differ materially from what is expressed or forecasted in such forward-looking statements due to numerous factors, including those described above and those risks discussed from time to time in AtheroNova, Inc. filings with the Securities and Exchange Commission. The company notes that the numbers contained in this release are unaudited, and are made in good faith and based on all the financial information available to the company today. Further, past financial business, operations and stock performance are not necessarily indicative of the company's future performance. The opinions expressed in the research report are the analyst's personal views about the company. Definitions of ratings are available to the public and to the analysts. No rating is to be issued that is labeled a recommendation. No analyst may recommend the purchase or the sale of any equity. The analyst is responsible only to the public and this report is not a service to the company. The report is for information purposes and is not intended as an offering or a solicitation to buy or sell the securities mentioned above. Neither the analyst nor Prime Equity Research owns any equity or debt securities in the analyzed company. Analysts are independent contractors and not employed by Prime Equity Research. The analyst is paid in advance to ensure independent and objective opinions are rendered without conflict. AtheroNova, Inc. and a Third party paid Prime Equity Research $12,500 for independent equity coverage. The following is from the Final Report of the SEC Advisory Committee on Smaller Public Companies, adopted February 21, 2006: www.sec.gov/info/smallbus/acspc/acspc-finalreport.pdf "In order to address the need for more independent research for smaller public companies, [the U.S. Securities and Exchange Advisory Committee on Smaller Public Companies recommends] that the Commission: "Maintain policies that allow company-sponsored research to occur with full disclosure by the research provider as to the nature of the relationship with the company being covered. "Entities providing such research should disclose and adhere to a set of ethical standards* that ensure quality and transparency and minimize conflicts of interest."
SOURCE AtheroNova Inc.
More by this Source
Atherosclerosis Researcher Dr. Erik Stroes Joins AtheroNova's Clinical Advisory Board
Oct 15, 2013, 07:00 ET
AtheroNova to Present at the 2013 Aegis Healthcare Conference in Las Vegas
Sep 19, 2013, 07:00 ET
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.